6 completed. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 3 |
Follow Entera Bio Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo EBP05, Forteo 0.02 mg, EBP11 - Hypoparathyroidism, Osteoporosis | Phase 1 | Completed | Entera Bio Ltd. | 45 | 2023-05-11 | 2026-02-17 |
| A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass EBP05, Placebo of EBP05 - Osteoporosis | Phase 2 | Completed | Entera Bio Ltd. | 161 | 2019-06-30 | 2021-06-28 |
| Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism EB612 (EBP05), NATPARA/NATPAR - Hypoparathyroidism | Phase 2 | Completed | Entera Bio Ltd. | 20 | 2018-06-17 | 2019-03-26 |
| A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism EnteraBio's Oral Parathyroid Hormone (1-34) - Hypoparathyroidism | Phase 2 | Completed | Entera Bio Ltd. | 20 | 2014-07-01 | 2015-10-07 |
| A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects Teriparatide, Oral PTH (1-34) - Drug Safety and Bioavailability | Phase 1 | Completed | Entera Bio Ltd. | 30 | 2013-10-01 | 2018-01-10 |
| A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects Teriparatide, placebo - Drug Safety | Phase 1 | Completed | Entera Bio Ltd. | 42 | 2011-07-01 | 2015-10-07 |
Hypoparathyroidism (3) · Osteoporosis (2) · Disease (1) · Fractures, Bone (1)
Teriparatide (5) · Parathyroid Hormone (2)
Israel (5)
Yosef Caraco, MD (3) · Arthur Santora, MD (2) · Sophia Ish Shalom, MD (1)